Conditional European approval for Fampyra for MS walking disability
This article was originally published in Scrip
Executive Summary
Following a reluctant recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in May, the European Commission has now conditionally approved Biogen Idec and Acorda Therapeutics' Fampyra (sustained-release fampridine), to improve walking in adult patients with multiple sclerosis (MS) who have walking disability.
You may also be interested in...
PML Case With Roche's Ocrevus, Link Unlikely
A German case of PML in a patient treated with Ocrevus, but who was also previously treated with Tysabri, threatens to take the gloss off Roche’s new multiple sclerosis therapy.
Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.